226 related articles for article (PubMed ID: 24382706)
1. Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a BCS class III Drug development candidate.
Kesisoglou F; Xie IH; Manser K; Wu Y; Hardy I; Fitzpatrick S
J Pharm Sci; 2014 Feb; 103(2):636-42. PubMed ID: 24382706
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
Kesisoglou F; Xia B; Agrawal NG
AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
[TBL] [Abstract][Full Text] [Related]
3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
4. Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption.
Kesisoglou F; Balakrishnan A; Manser K
J Pharm Sci; 2016 Feb; 105(2):722-728. PubMed ID: 26457884
[TBL] [Abstract][Full Text] [Related]
5. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
[TBL] [Abstract][Full Text] [Related]
6. Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics.
Kim TH; Bulitta JB; Kim DH; Shin S; Shin BS
Int J Pharm; 2019 Feb; 556():276-286. PubMed ID: 30543888
[TBL] [Abstract][Full Text] [Related]
7. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers.
Kesisoglou F; Rossenu S; Farrell C; Van Den Heuvel M; Prohn M; Fitzpatrick S; De Kam PJ; Vargo R
J Pharm Sci; 2014 Nov; 103(11):3713-3723. PubMed ID: 25256703
[TBL] [Abstract][Full Text] [Related]
8. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL
Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity.
Radwan A; Amidon GL; Langguth P
Biopharm Drug Dispos; 2012 Oct; 33(7):403-16. PubMed ID: 22782559
[TBL] [Abstract][Full Text] [Related]
12. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
[TBL] [Abstract][Full Text] [Related]
13. Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS).
Christiansen ML; Holm R; Kristensen J; Kreilgaard M; Jacobsen J; Abrahamsson B; Müllertz A
Eur J Pharm Sci; 2014 Jun; 57():164-72. PubMed ID: 24239996
[TBL] [Abstract][Full Text] [Related]
14. Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
Good DJ; Hartley R; Mathias N; Crison J; Tirucherai G; Timmins P; Hussain M; Haddadin R; Koo O; Nikfar F; Fung NK
Mol Pharm; 2015 Dec; 12(12):4434-44. PubMed ID: 26536519
[TBL] [Abstract][Full Text] [Related]
15. Fed and fasted state gastro-intestinal in vitro lipolysis: In vitro in vivo relations of a conventional tablet, a SNEDDS and a solidified SNEDDS.
Christophersen PC; Christiansen ML; Holm R; Kristensen J; Jacobsen J; Abrahamsson B; Müllertz A
Eur J Pharm Sci; 2014 Jun; 57():232-9. PubMed ID: 24056027
[TBL] [Abstract][Full Text] [Related]
16. Utility of Göttingen minipigs for Prediction of Human Pharmacokinetic Profiles After Dermal Drug Application.
Yamamoto S; Karashima M; Sano N; Fukushi C; Tohyama K; Arai Y; Hirabayashi H; Amano N
Pharm Res; 2017 Nov; 34(11):2415-2424. PubMed ID: 28828717
[TBL] [Abstract][Full Text] [Related]
17. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
Franek F; Holm P; Larsen F; Steffansen B
Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
[TBL] [Abstract][Full Text] [Related]
18. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
Cao QR; Choi YW; Cui JH; Lee BJ
J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
[TBL] [Abstract][Full Text] [Related]
19. Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls.
Kesisoglou F; Hermans A; Neu C; Yee KL; Palcza J; Miller J
J Pharm Sci; 2015 Sep; 104(9):2913-22. PubMed ID: 25611455
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
